NCT03595813

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy

Identifying Immune-related Biomarkers to Predict the Efficacy of Cancer Immunotherapy-IMMUNO-SUP-IPC 2017-002

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 135 (actual)
• Sponsor: Institut Paoli-Calmettes · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The development of Immune Checkpoint Blockade (ICB) is a revolution in medical oncology as ICB have changed the standard treatments of several metastatic tumor types. However, the response rate to ICB is low, and the biological bases for this response heterogeneity are poorly understood. In the frame of Immunosup study, we will collect blood (at baseline, post infusion of ICB n°2/4/8 and at progression) and tumor samples (optional: at baseline and progression) from patients with locally advanced or metastatic cancer, treated with ICB, in order to determine if the dynamics of immunosuppressive actors (MDSC, TReg, Immunosuppressive cytokines) predicts response to these immunotherapies.

Conditions

• Lung Cancer Metastatic
• Locally Advanced Malignant Neoplasm
• Non Hodgkin Lymphoma
• Urologic Neoplasms

Interventions

Type	Name	Description
PROCEDURE	Blood sample collection	Blood samples collection (5EDTA vials) at baseline, post infusion of ICB n°2/4/8 and at progression
PROCEDURE	Biopsy collection	Optional biopsy collection at baseline and progression

Timeline

• Start date: 2018-01-29
• Primary completion: 2020-07-17
• Completion: 2025-07-01
• First posted: 2018-07-23
• Last updated: 2021-03-29

Locations

1 site across 1 country: France